USD 9.28
(33.91%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 330.32 Million USD | 17.39% |
2022 | 281.39 Million USD | 214.11% |
2021 | 89.58 Million USD | -53.59% |
2020 | 193.02 Million USD | 1.06% |
2019 | 190.98 Million USD | 23.42% |
2018 | 154.74 Million USD | -0.68% |
2017 | 155.8 Million USD | 29.68% |
2016 | 120.14 Million USD | 94.08% |
2015 | 61.9 Million USD | 0.0% |
2014 | - USD | 0.0% |
2013 | - USD | 0.0% |
2012 | - USD | 0.0% |
2011 | - USD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q1 | 414.34 Million USD | 25.43% |
2024 Q2 | 390.42 Million USD | -5.77% |
2023 Q4 | 330.32 Million USD | 8.76% |
2023 Q3 | 303.7 Million USD | -1.03% |
2023 Q2 | 306.85 Million USD | 12.25% |
2023 Q1 | 273.37 Million USD | -2.85% |
2023 FY | 330.32 Million USD | 17.39% |
2022 Q4 | 281.39 Million USD | 1.14% |
2022 Q2 | 292.96 Million USD | 165.52% |
2022 Q1 | 110.33 Million USD | 23.17% |
2022 FY | 281.39 Million USD | 214.11% |
2022 Q3 | 278.21 Million USD | -5.04% |
2021 Q1 | 205.76 Million USD | 6.6% |
2021 Q2 | 198.6 Million USD | -3.48% |
2021 FY | 89.58 Million USD | -53.59% |
2021 Q3 | 181.56 Million USD | -8.58% |
2021 Q4 | 89.58 Million USD | -50.66% |
2020 Q4 | 193.02 Million USD | -1.16% |
2020 Q3 | 195.29 Million USD | -0.12% |
2020 Q1 | 200.34 Million USD | 4.9% |
2020 Q2 | 195.51 Million USD | -2.41% |
2020 FY | 193.02 Million USD | 1.06% |
2019 Q2 | 194.22 Million USD | 4.55% |
2019 FY | 190.98 Million USD | 23.42% |
2019 Q4 | 190.98 Million USD | -2.54% |
2019 Q3 | 195.95 Million USD | 0.89% |
2019 Q1 | 185.76 Million USD | 20.05% |
2018 Q1 | 155.59 Million USD | -0.13% |
2018 FY | 154.74 Million USD | -0.68% |
2018 Q4 | 154.74 Million USD | -0.19% |
2018 Q3 | 155.03 Million USD | -0.18% |
2018 Q2 | 155.31 Million USD | -0.18% |
2017 Q1 | 147.55 Million USD | 22.82% |
2017 Q2 | 153.96 Million USD | 4.34% |
2017 FY | 155.8 Million USD | 29.68% |
2017 Q4 | 155.8 Million USD | 0.48% |
2017 Q3 | 155.05 Million USD | 0.71% |
2016 Q3 | 99.99 Million USD | 15.43% |
2016 Q4 | 120.14 Million USD | 20.15% |
2016 Q1 | 74.41 Million USD | 20.21% |
2016 Q2 | 86.62 Million USD | 16.41% |
2016 FY | 120.14 Million USD | 94.08% |
2015 Q2 | - USD | 0.0% |
2015 Q3 | 43.77 Million USD | 0.0% |
2015 Q4 | 61.9 Million USD | 41.4% |
2015 Q1 | - USD | 0.0% |
2015 FY | 61.9 Million USD | 0.0% |
2014 Q3 | - USD | 0.0% |
2014 Q1 | - USD | 0.0% |
2014 Q4 | - USD | 0.0% |
2014 Q2 | - USD | 0.0% |
2014 FY | - USD | 0.0% |
2013 Q2 | - USD | 0.0% |
2013 FY | - USD | 0.0% |
2013 Q4 | - USD | 0.0% |
2013 Q3 | - USD | 0.0% |
2013 Q1 | - USD | 0.0% |
2012 FY | - USD | 0.0% |
2012 Q4 | - USD | 0.0% |
2011 FY | - USD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Editas Medicine, Inc. | 36.53 Million USD | -804.111% |
Dynavax Technologies Corporation | 256.91 Million USD | -28.575% |
Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -695.449% |
Perrigo Company plc | 4.07 Billion USD | 91.891% |
Illumina, Inc. | 2.26 Billion USD | 85.397% |
Thermo Fisher Scientific Inc. | 34.91 Billion USD | 99.054% |
Iovance Biotherapeutics, Inc. | 1 Million USD | -32932.6% |
Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 96.543% |
IQVIA Holdings Inc. | 14.23 Billion USD | 97.679% |
Heron Therapeutics, Inc. | 173.75 Million USD | -90.112% |
Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 87.779% |
Unity Biotechnology, Inc. | 26.99 Million USD | -1123.883% |
Waters Corporation | 2.35 Billion USD | 85.976% |
Biogen Inc. | 7.33 Billion USD | 95.499% |
Sangamo Therapeutics, Inc. | 38.1 Million USD | -766.906% |
Evolus, Inc. | 126.54 Million USD | -161.032% |
Adicet Bio, Inc. | 17.7 Million USD | -1765.932% |
Cara Therapeutics, Inc. | 43.16 Million USD | -665.228% |
Esperion Therapeutics, Inc. | 540.94 Million USD | 38.936% |
FibroGen, Inc. | 170.45 Million USD | -93.791% |
Agilent Technologies, Inc. | 2.73 Billion USD | 87.922% |
Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -1481.7% |
Homology Medicines, Inc. | 44.05 Million USD | -649.821% |
Geron Corporation | 85.89 Million USD | -284.552% |
Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 86.225% |
Amicus Therapeutics, Inc. | 445.05 Million USD | 25.779% |
Myriad Genetics, Inc. | 145 Million USD | -127.811% |
Viking Therapeutics, Inc. | 1.26 Million USD | -26116.349% |
Intellia Therapeutics, Inc. | 115.34 Million USD | -186.378% |
Zoetis Inc. | 6.8 Billion USD | 95.144% |
Abeona Therapeutics Inc. | 4.4 Million USD | -7403.998% |
Mettler-Toledo International Inc. | 2.16 Billion USD | 84.762% |
BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 70.868% |
Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 59.138% |
Kala Pharmaceuticals, Inc. | 36.32 Million USD | -809.413% |
Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 77.274% |
Atara Biotherapeutics, Inc. | 57.87 Million USD | -470.787% |
Verastem, Inc. | 41.55 Million USD | -694.875% |
Nektar Therapeutics | 230.4 Million USD | -43.37% |
Axsome Therapeutics, Inc. | 186.37 Million USD | -77.24% |
Aclaris Therapeutics, Inc. | 3.07 Million USD | -10645.804% |
Sarepta Therapeutics, Inc. | 1.39 Billion USD | 76.351% |
OPKO Health, Inc. | 326.56 Million USD | -1.152% |
Exelixis, Inc. | 189.94 Million USD | -73.907% |
Neurocrine Biosciences, Inc. | 428.4 Million USD | 22.893% |
Corcept Therapeutics Incorporated | 151 Thousand USD | -218658.94% |
Anavex Life Sciences Corp. | - USD | -Infinity% |
uniQure N.V. | 138.4 Million USD | -138.659% |
Imunon, Inc. | 1.13 Million USD | -28893.946% |
Blueprint Medicines Corporation | 774.12 Million USD | 57.329% |
Insmed Incorporated | 1.2 Billion USD | 72.564% |
Halozyme Therapeutics, Inc. | 1.49 Billion USD | 77.967% |
Agios Pharmaceuticals, Inc. | 56.98 Million USD | -479.641% |
TG Therapeutics, Inc. | 110.79 Million USD | -198.142% |
Incyte Corporation | 38.28 Million USD | -762.763% |
Emergent BioSolutions Inc. | 877.5 Million USD | 62.356% |